shutterstock_2

GSK confirms deal to supply 300 million COVID-19 vaccine doses to the EU

pharmafile | September 25, 2020 | News story | Manufacturing and Production, Medical Communications COVID-19, EU, GSK, Vaccine 

GlaxoSmithKline has confirmed a new COVID-19 vaccine supply deal to deliver 300 million doses of its candidate to the European Commission.

On the condition that the vaccine secures regulatory approval, all European Union member states will be eligible to access the therapy.

Under the terms of the agreement, the EU will also have the option to provide a proportion of the reserved doses to low and middle-income nations. The EU has also committed upfront funding to support the scale-up of the project.

The confirmation of the partnership follows an initial announcement on 31 July.

Advertisement

The candidate combines Sanofi’s Influenza vaccine platform with GSK’s adjuvant technology. It is currently undergoing Phase 1/2 trials, with a Phase 3 study planned for the end of the year.

“Both companies have significant research and development and manufacturing capability in Europe and are already working hard to scale up production across our networks,” Roger Connor, President of GSK vaccines, said of the deal. “This announcement from the European Commission supports our ongoing efforts.”

Matt Fellows

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

drug-trials

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Sharp invests $100m in US and EU manufacturing and packaging facilities

Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

The Gateway to Local Adoption Series

Latest content